GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Imipenem / cilastatin / relebactam (Recarbrio)

Local official-label summaryBase record retrieved 2026-09-05See the evidence for this drug2 sources available - open source summaries, references and comparisons

Recarbrio

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

RECARBRIO - adult renal dosing

Product / population
Adults; exact named U.S. product. Selected dose/renal summary, not the full prescribing information.
Renal measure
Cockcroft-Gault CrCl, mL/min, for adults.

Dosing / renal protocol and limits

All adult doses are total combination amounts, given IV every 6 hours over 30 minutes.

Cockcroft-Gault CrCl (mL/min)Dose
>=901.25 g (500/500/250 mg)
60-891 g (400/400/200 mg)
30-590.75 g (300/300/150 mg)
15-29 without HD0.5 g (200/200/100 mg)
Receiving HD0.5 g (200/200/100 mg)

Components are imipenem/cilastatin/relebactam. Below 15 without HD, use is not recommended; do not administer unless HD will begin within 48 hours. For established HD, give after the session and time subsequent intervals from session end. Peritoneal-dialysis dosing is not established. The label course is 4-14 days according to indication/response. Pediatric weight/eGFR schedules are separate.

Source revision: Label updated 2025-12-09. | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=be32f468-738b-40df-a425-591e12f65159

Scope: Locally included source-specific summary. Regimen differences are not automatically resolved. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Official product label

RECARBRIO - adult renal dosing

Adults; exact named U.S. product. Selected dose/renal summary, not the full prescribing information.

Renal method: Cockcroft-Gault CrCl, mL/min, for adults.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
Professional guidance

UCSF - RECARBRIO

Adults; imipenem/cilastatin/relebactam total combined IV dose; not imipenem/cilastatin alone.

Renal method: CrCl in mL/min where specified; no equation inferred.
Retrieved: 2026-09-05

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeRECARBRIO - adult renal dosingUCSF - RECARBRIO
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=be32f468-738b-40df-a425-591e12f65159

Product and population scope

Adult Imipenem / cilastatin / relebactam (Recarbrio). Use only the product, route, indication and renal-replacement setting explicitly stated in the source protocol selected below. Sources are alternatives to compare, not ingredients of a blended regimen.

SCOPE-imipenem-cilastatin-relebactam · Source section: Editorial scope; each clinical recommendation is separately attributed belowRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

RECARBRIO - adult renal dosing

Open original reference

Open / share this exact local source

NIH/NLM DailyMed - U.S. product labeling · Adults; exact named U.S. product. Selected dose/renal summary, not the full prescribing information.

Renal method: Cockcroft-Gault CrCl, mL/min, for adults.
Source date: Label updated 2025-12-09.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

All adult doses are total combination amounts, given IV every 6 hours over 30 minutes.

Cockcroft-Gault CrCl (mL/min)Dose
>=901.25 g (500/500/250 mg)
60-891 g (400/400/200 mg)
30-590.75 g (300/300/150 mg)
15-29 without HD0.5 g (200/200/100 mg)
Receiving HD0.5 g (200/200/100 mg)

Components are imipenem/cilastatin/relebactam. Below 15 without HD, use is not recommended; do not administer unless HD will begin within 48 hours. For established HD, give after the session and time subsequent intervals from session end. Peritoneal-dialysis dosing is not established. The label course is 4-14 days according to indication/response. Pediatric weight/eGFR schedules are separate.

RDM30-070-imipenem-cilastatin-relebactam-1 · Source locator: RECARBRIO - adult renal dosing; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=be32f468-738b-40df-a425-591e12f65159
Retrieved
2026-09-05
DailyMed Set ID
be32f468-738b-40df-a425-591e12f65159
Renal-function method
Cockcroft-Gault CrCl, mL/min, for adults.
Source date/version
Label updated 2025-12-09.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
03b7654bfa175e14d2a613f6886ec6dc4ea4a70d9ad5dad12970c7e7127f1e9f
Separate professional-source layer

University and professional protocols

Professional

UCSF - RECARBRIO

Open original reference

Open / share this exact local source

UCSF Infectious Diseases Management Program · Adults; imipenem/cilastatin/relebactam total combined IV dose; not imipenem/cilastatin alone.

Renal method: CrCl in mL/min where specified; no equation inferred.
Source date: Revision date not stated in the reviewed page.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

Total combined IV doses every 6 hours: CrCl >90, 1.25 g; 60-90, 1 g; 30-60, 750 mg; 15-30, 500 mg. A 1.25 g dose comprises imipenem 500 mg, cilastatin 500 mg and relebactam 250 mg.

IHD: 500 mg every 6 hours. Continuous-HD dosing is not supplied. The website's adjacent renal ranges overlap at their exact endpoints; use the separately listed label boundaries when an exact 30, 60 or 90 mL/min value must be assigned.

RDM30-009-imipenem-cilastatin-relebactam-1 · Source locator: UCSF - RECARBRIO; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://idmp.ucsf.edu/content/imipenem-cilastatin-relebactam
Retrieved
2026-09-05
Renal-function method
CrCl in mL/min where specified; no equation inferred.
Source date/version
Revision date not stated in the reviewed page.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
927e797e871f853cca711d6e593343cebf7a9f0d8ad0338d8e165f50ccc7097c

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 0 RX List, 1 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=be32f468-738b-40df-a425-591e12f65159
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
multisource addition
Local text SHA-256
f557145282a4fc6f2dfcd296d43cd8eb7ced4875174648638d9729bcd70a137c
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report